Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

onClick="var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='93665764';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.aezsinc.com">www.aezsinc.com. A replay will be available on the Company's website for 30 days following the live event.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... ANNAPOLIS, Maryland , 15. September 2014 /PRNewswire/ ... Week (IPAW) wird vom 12. bis 18. ... der Plasma Protein Therapeutics Association (PPTA) ... Ziele: , Das globale Bewusstsein für ... Den Beitrag von Plasmaspendern beim Retten und Verbessern ...
(Date:9/14/2014)... September 15, 2014 UMBC’s Biotechnology ... on Tuesday, October 21, 2014, from 12:00 to 1:00 ... the program’s innovative curriculum and practice-oriented instruction, designed for ... degree can help advance their career in the biotechnology ... online . , About UMBC’s Biotechnology Graduate Programs, ...
(Date:9/12/2014)... AMSTERDAM , Sept. 12, 2014   Arthur ... startup bio-bean, has won the Postcode Lottery Green Challenge ... awarded Kay euro 500,000 ($680,000 USD) at the final ... green business plan. Kay,s company uses ... advanced biofuel products, namely biodiesel and biomass pellets, used ...
(Date:9/12/2014)... 12, 2014 Sandia Biotech, Inc. announced ... agreement with STC.UNM (STC) for a technology developed by ... Albuquerque, New Mexico, and Queen Mary University of London ... the Recombinant Fluorescent Antibody Technology Platform (RFAP) was developed ... Medicine and Dr. Angray Kang from Queen Mary’s Department ...
Breaking Biology Technology:International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 4
... Corporation,s (Amex: ETC ) ("ETC" or the ... two (2) BARA-MED(R),Monoplace Hyperbaric Chambers at East Orange ... is a fully accredited, acute care hospital,located in ... of East Orange,General Hospital is run by Dr. ...
... of Enrollment in U.S. Phase II Study,of Nitazoxanide ... TAMPA, Fla., Oct. 28 Romark Laboratories, ... of studies,of nitazoxanide at the upcoming 59th Annual ... Liver Diseases (AASLD), also known as The,Liver Meeting(R), ...
... N.J., Oct. 28 BioWa, Inc. announced ... with KaloBios Pharmaceuticals, Inc.,under which BioWa licenses ... antibody-dependent cellular cytotoxicity (ADDC) of select,KaloBios therapeutic ... strategic partnership with KaloBios,",commented Dr. Masamichi Koike, ...
Cached Biology Technology:Environmental Tectonics Corporation's BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital 2Environmental Tectonics Corporation's BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital 3Environmental Tectonics Corporation's BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital 4Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2BioWa Announces License of Biowa's Potelligent(R) Technology to KaloBios Pharmaceuticals 2
(Date:9/15/2014)... wild, domesticated, and domesticated-wild hybridized populations of ... that within 5 to 11 generations, selection ... populations that hybridized with domesticated populations. , ... evidence that natural selection, over time, removes ... as a result of increased genetic diversity. ...
(Date:9/15/2014)... Ebola virus outbreak in West Africa, which has claimed ... a deeper understanding of the molecular biology of the ... vaccines or antiviral drugs to treat or prevent Ebola ... Virginia (UVA), USA under the leadership of Dr ... structural biologist has obtained the crystal structure of ...
(Date:9/15/2014)... cardiovascular disease (CVD) claims 17 million lives each year, ... 9.4 million. 1 New research presented by international ... Montpellier, France on September 15, 2014, suggests that milk ... , At the Milk and Dairy Products in ... risk for hypertension and CVD was examined by Dr. ...
Breaking Biology News(10 mins):Protein secrets of Ebola virus 2Dairy consumption linked to lower blood pressure and cardiovascular disease risk 2
... join the two copies of each chromosomecalled sister chromatidsto ... cells during cell division. In this way, each daughter ... parent cell. Pds5 is a protein associated with ... vertebrates there are two variants of Pds5, Pds5A and ...
... industrial cities is often an overlooked resource. Years of manufacturing ... and scare residents away from using the land. As the ... the desire to grow food in cities with the fear ... at 10:35 am, Kristen McIvor of the Pierce Conservation District ...
... Zhang, a biochemist and geneticist with Texas A&M AgriLife ... million from the National Science Foundation to further his ... ultimately could help breed more productive plants. The ... is given in "support of junior faculty who exemplify ...
Cached Biology News:CNIO researchers delve into the behavior of cohesins 2Fostering community gardens in an area with historic soil contamination 2AgriLife researcher Xiuren Zhang receives National Science Foundation CAREER grant 2
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
...
...
...
Biology Products: